- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04:26 | Patient Death Drags Erasca (ERAS) Shares by 48% | 3 | Insider Monkey | ||
| Di | TD Cowen bekräftigt Kaufempfehlung für Revolution Medicines nach Daten von Konkurrent Erasca | 18 | Investing.com Deutsch | ||
| Di | FDA claims Amgen drug data were 'manipulated'; Erasca slides despite 'home run' results | 13 | BioPharma Dive | ||
| Di | Erasca hits 'home run' with cancer data as analyst suggests stock drop prompted by patient death | 4 | FierceBiotech | ||
| Di | H.C. Wainwright reiterates Erasca stock rating on phase 1 data | 3 | Investing.com | ||
| ERASCA Aktie jetzt für 0€ handeln | |||||
| Di | Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy | 16 | Seeking Alpha | ||
| Di | BofA raises Erasca stock price target to $9 on trial data | 6 | Investing.com | ||
| Mo | Erasca meldet positive frühe Studiendaten für Pan-RAS-Medikament | 3 | Investing.com Deutsch | ||
| Mo | Erasca reports positive early trial data for pan-RAS drug | 11 | Investing.com | ||
| Mo | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | 118 | GlobeNewswire (Europe) | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| Mo | Stifel raises Erasca stock price target to $30 on RAS program | 16 | Investing.com | ||
| 21.04. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.04. | Jefferies reiterates Erasca stock Buy rating ahead of ASCO data | 7 | Investing.com | ||
| 13.04. | Jefferies reiterates Erasca stock Buy rating on rival trial data | 2 | Investing.com | ||
| 13.04. | Jefferies bestätigt Kaufempfehlung für Erasca nach Studiendaten von Konkurrent | 4 | Investing.com Deutsch | ||
| 10.04. | What's Driving Erasca (ERAS)'s Nearly 355% YTD Return | 3 | Insider Monkey | ||
| 20.03. | Erasca (ERAS) Adds 13%; Soars 310% YTD | 1 | Insider Monkey | ||
| 12.03. | Erasca GAAP EPS of -$0.19 | 1 | Seeking Alpha | ||
| 12.03. | Erasca, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.03. | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | 347 | GlobeNewswire (Europe) | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,15 | -1,15 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| MODERNA | 38,890 | -3,37 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| PAION | 0,047 | -26,19 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NOVAVAX | 6,650 | -1,77 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| ILLUMINA | 102,90 | -5,04 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| NANOREPRO | 1,535 | -0,32 % | Original-Research: NanoRepro AG (von NuWays AG): KAUFEN | Original-Research: NanoRepro AG - von NuWays AG
22.04.2026 / 09:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results - Without Animal Testing | ||
| INOVIO PHARMACEUTICALS | 0,988 | +0,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| INFLARX | 1,491 | +4,19 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| SCORPIUS | - | - | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,320 | -5,60 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Grant of Restricted Stock Units | Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| EDITAS MEDICINE | 2,390 | -8,78 % | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | ||
| BIOCRYST PHARMACEUTICALS | 7,652 | +1,16 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| IBIO | 1,511 | +8,86 % | iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 |
ERASCA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -6,27 % bei einem Aktienkurs von 9,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERASCA INC finden Sie auf Wallstreet Online.